Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood FlowCaroline J. Breitbach, John C. Bell, Jennifer M Paterson et al.|Molecular Therapy|2007Cited by 277
Targeting Tumor Vasculature With an Oncolytic VirusCaroline J. Breitbach, John C. Bell, Naomi S. De Silva et al.|Molecular Therapy|2011Cited by 202
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisThi Lien-Anh Nguyên, John Hiscott, Hesham Abdelbary et al.|Proceedings of the National Academy of Sciences|2008Cited by 182
VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus InfectionRozanne Arulanandam, John C. Bell, Cory Batenchuk et al.|Cancer Cell|2015Cited by 104
Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus MacaquesLaura Evgin, J. Andrea McCart, Sergio A. Acuña et al.|Molecular Therapy|2015Cited by 80